Huahai Pharmaceutical's Subsidiaries Receive Approval for Clinical Trial of HB0056 Injection for Idiopathic Pulmonary Fibrosis

Gelonghui, June 2 |Huahai Pharmaceutical(600521.SH) announced that recently, its subsidiary Shanghai HuaAotai BiotechPharmaceutical Co., Ltd. and Huabo Biomedical Technology (Shanghai) Co., Ltd. have received the "Notice of Approval for Drug Clinical Trials" for the new indication of HB0056 Injection, approved and issued by the National Medical Products Administration. Drug Name: HB0056 Injection; Indication: Idiopathic Pulmonary Fibrosis.

The research and development of pharmaceutical products, including clinical trials and the cycle from regulatory submission to industrialized production, is characterized by a long duration and numerous stages. It is subject to various uncertainties, such as technical challenges and regulatory reviews, while the competitive landscape for future products is also expected to evolve.